Amgen Inc

Amgen Inc.’s stock price has surged due to positive news from its clinical trials, particularly the Phase 3 FORTITUDE-101 trial, which demonstrated the effectiveness of bemarituzumab in treating gastric cancer.

Amgen’s experimental weight-loss drug MariTide has yielded promising results in a phase 2 study, with patients achieving significant weight loss without plateauing, despite a temporary dip in the company’s share price.

Amgen’s presentation at the Goldman Sachs conference comes as the broader market experiences a welcome uptrend, with the Dow Jones index rising 0.964% since the start of 2025.

Amgen will showcase its leadership expertise at the Jefferies Global Healthcare Conference, providing investors and stakeholders with valuable insights into the company’s strategic direction and market outlook.

Amgen has secured marketing authorization in the UK for its TEPEZZA treatment, marking a major milestone in the fight against thyroid eye disease.

Amgen’s Q1 2025 earnings report exceeded expectations, with top-line growth driven by key drugs, including biosimilar Stelara, solidifying the company’s momentum in the biotech space.

Amgen’s stock has surged as the biotech giant invests $200 million in a new technology center in India, signaling a renewed focus on growth and innovation.

Amgen’s recent announcement and strong quarterly earnings have sparked investor enthusiasm, solidifying its position as a market leader and fueling optimism about its future prospects.

Amgen’s stock price sees mixed trends due to a clinical hold on its obesity treatment candidate, but the company remains optimistic about its future prospects and forecasts revenue growth in 2025.